Pharma Social Media and Updates
Pharma Social Media and Updates
We are very happy to join forces together with the wonderful ASKA to go after Novel Targets for Women's Health. Gynecological diseases have long posed challenges, including difficult diagnosis, limited treatment options, and a substantial disease burden, affecting millions of patients worldwide. According to estimates from the World Health Organization, endometriosis affects approximately 190 million women globally, while uterine fibroids and adenomyosis impact an even larger demographic, often co-occurring and heavily impacting women's reproductive health.This collaboration combines ASKA’s deep expertise in gynecological therapeutics with Insilico Medicine’s advanced AI-driven biological analytics capabilities to address major unmet medical needs affecting hundreds of millions of patients worldwide and to accelerate the development of innovative solutions. Under the partnership, Insilico will leverage PandaOmics to identify and explore disease hypotheses, while ASKA will validate the AI-predicted therapeutic targets with high translational potential. https://t.co/UM9qfRbpi8
Blood levels of the Alzheimer's biomarker p-tau217 may help identify which women are more vulnerable to dementia when using combined hormone therapy after menopause, while estrogen-only therapy does not show the same association. menopause
A potentially game-changing discovery by @UCSF's Justin Eyquem @j_eyquem & colleagues – injecting cancer-fighting immune cells directly into the body kills several types of cancers in mice. Paper in @Nature: https://t.co/EXbsfx7whl Summary/video by UCSF: https://t.co/qLYXXvEDTV
One of the most remarkable things about 5-meo-DMT as an antidepressant is that the psychoactive experience is so brief. 10 minute peak, perhaps. 20 min total. And people seldom remember it well. Yet it has possibly the largest anti-depressant effect...
Another win for Dizal, but how do US patients get hold of Zegfrovy? Via @ApexOnco -> https://t.co/4GVjyHS9vz https://t.co/bjjrnZkNL6
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares https://t.co/BCRJAUwGIJ $INSM + 7% $SRPT $SNY $GSK #biotech
As someone who lived in Vermont and still spends the summer there, it's disappointing to see the ambiguity in Pfizer's data on a new Lyme disease vaccine. It's a serious threat. Now we can move on to speculating on the...
Paradox: The FDA approved some fecal transplants for C. difficile. But accessing treatment got harder. https://t.co/AFFyCGPeKW
The news is mixed in the preliminary results from a Phase 3 trial of a needed #Lyme disease vaccine, @matthewherper reports. https://t.co/bcbfeXchk1
The $PFE/ $VALN Lyme vaccine was a product for which there was a lot of hope. Results today show OK efficacy. Vaccine efficacy landed at 70%; investors hoped for 80% but thought as low as 60% would be relevant. But the...
From Prognosis to Action: Circulating Tumor DNA and the Next Phase of Risk Stratification in Triple-Negative Breast Cancer [Mar 18, 2026] Schneider & @StoverLab @JCO_ASCO https://t.co/6jPBxQe9QP #bcsm #PrecisionMedicine #LiquidBiopsy https://t.co/MOG73iTcNl
Guideline Update Provides New Testing & Tx Recx for Pts w/ ER-Positive, HER2-Negative Met Breast Cancer w/ ESR1 Mutations [May 17-18, 2023] @ASCO Daily News - https://t.co/3ZVrEkQEN5 @DrHBurstein et al. @JCO_ASCO https://t.co/68e7D0CSgU #bcsm #PrecisionMedicine #LiquidBiopsy https://t.co/KBx2hq2BDW
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol https://t.co/hXxlFINejC #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm https://t.co/3Pa2TRMntk
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer [Dec 15, 2021] Schneider et al. Radovich @JCO_ASCO https://t.co/oJm6BJrMtA #bcsm #PrecisionMedicine
Genome-Wide Associations [GWAS] and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors [Sep 20, 2010] Ingle et al. @DrWeinshilboum @JCO_ASCO https://t.co/1NJcXkWy8c #bcsm #Supponc
Assoc of Circulating Tumor DNA & Circulating Tumor Cells After Neoadjuvant Chemotherapy w/ Disease Recurrence in Pts w/ Triple-Negative Breast Cancer: BRE12-158 RCT [Jul 9, 2020] Radovich et al. @JAMAOnc https://t.co/XxH9kTT9d5 #bcsm #cactc #NCT02101385 https://t.co/kgV0yM2I1f
Pfizer's phase 3 for its Lyme trial was supposed to be 18k patients -- but issues with a contractor at the start of the trial cut the size by a third, and @ky_lahucik + I reported a long time ago...
P7C3 is an activator of an enzyme that makes NAD called NAMPT. Cool that it’s working in a 🐁 model of AD 👏
New @nberpubs: "From Free Rider to Innovator: The Rise of China's Drug Development" https://t.co/cQpEqRC1jy https://t.co/pSL5kCzlnO
Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle There is a set up for drama here. $Valn $pfe Valneva stock is down 14% in premarket trading. https://t.co/WN0KOl4Nqh via @statnews
Peptides are all the rage right now, but it’s hard to see how they are different from the previous generations of snake oils. The principle that anything that makes a health claim should have to justify it with scientific evidence...
7 Drugs. 30,000 Mice. 20 Years. The Only Longevity Compounds With Real Evidence. https://t.co/BzdoDZeicb @agingroy https://t.co/uM5QMpIAS6
Very important paper from our & @liquidai teams - deeply honored to have published with the geniuses @ramin_m_h & @xanamini . Take the super flexible model with high density of intelligence, post-train and fine-tune for basic...
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty 🌟Performance on the 6-minute walk test improved in a dose-response fashion 🌟Improved 6-minute walk test distance correlated with patient-reported outcomes 🌟The percentage of study subjects classified as frail decreased...
Stem cell therapy shows promise for reversing aging-related frailty in new clinical trial 🗣️A clinical trial reports that a single dose can significantly improve physical strength and key signs of aging in older adults with frailty. https://t.co/5mw5r64imb https://t.co/uI88QpTEIa
“At least two career staffers at the FDA whose work includes compounding drugs said they learned of the health secretary’s plans to take action on peptides only from his appearance on Rogan’s podcast.” https://t.co/vpTDqstpDZ
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial “Treated groups had remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome. Given the excellent safety and efficacy...
Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice https://t.co/k0vERH4LSg
But…I develop low-cost often patent free vaccines that bypass big pharma and provide access to people who can’t afford them. In the past people who espoused freedom were learned and read books. Now they’re just lazy mindless dummies who think...
The biotech industry spends $3 billion and 13 years to bring one drug to market. If you're still searching for a treatment that works, it exists but the process discovering it is too slow to actually help you in time. How Marc...
Scientists who stick their necks out and make medicines are my heroes There’s too much concern about COI for seasoned scientists with exemplary records Without commercial activity, we’d have zero medicines and ER-100 would still be in mice, not FDA cleared for...
It follows that if TADs are biased by expectancy, Open Label trials will show better outcomes than blinded. Further, if expectancy is not a strong driver of response to psychedelics, then blinding shouldn’t matter as much. This is what they...
I bet on uniQure thinking it was an obvious win win win. HD wins with expanded access. FDA wins by narrowly expanding authorization while vigorously monitoring follow up data. Investors win as the company proves what doctors are saying. Instead...
Use of SGLT2 Inhibitors in Frail Older Adults is Associated with Increased Survival: A Retrospective Study https://t.co/tsJ5qJLBap https://t.co/4EvBWDftJ4
Effect of henagliflozin on aging biomarkers in patients with type 2 diabetes: A multicenter, randomized, double-blind, placebo-controlled study 🔎"Our results suggest that henagliflozin may exert anti-aging effects by influencing multiple pathways, including the IGF-1 system, glucose metabolism, the immune system, and...
3 Questions: Using AI to accelerate the discovery and design of therapeutic drugs | MIT News | Massachusetts Institute of Technology https://t.co/CZ4waA5IGg
Read “Bottle of Lies.” FDA needs to perform spot checks of generics - not just inspections.
Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma [Dec 12, 2021] Dai et al. Abstract 459 #ASH21 https://t.co/mnXEThuKgy #mmsm #PrecisionMedicine https://t.co/zx7d29Jzpk
To appeal or not to appeal (yet): The potentially politically dicey situation facing HHS over a preliminary court ruling this week on #ACIP and the rewritten childhood vaccination schedule. By @ChelseaCirruzzo. https://t.co/3P1PW1lDFT
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/acq0EeyNFn
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/s8eqQJkQzK
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/lI3MqKHIiY
Oh, *now* the FDA has decided to have a public hearing on the national priority review voucher program. After four drugs have completed the process. A year after the program was announced. This must be that "radical transparency" that @DrMakaryFDA...
AI didn’t just enter biology. It’s starting to rebuild it from first principles. @MichaBreakstone sold his last company for $575M. Then he went after a harder problem. What if you could model how cells signal, respond, and adapt… before you ever run an...
This is a recurrent fiasco. Health care companies that now the serious risk of their device or drug but keep selling it and do not acknowledge the hazard. Until so many people are harmed. Today's front page @nytimes by @katie_thomas @bostonsci...
Why should tumor whole genome sequencing (WGS) be done for cancer? In real practice of medicine study of 888 patients with solid cancers, WGS directly led to clinical consequences in over 40% @NatureMedicine https://t.co/kFho0yuLS7
Giant biotech round that hit right after I sent Pro Rata: Earendil Labs raises $787M https://t.co/NWt2bBA9Lr
caveat here is that it was routine when Prasad ran CBER (at least 4 overrules in Prasad's 10 mo. tenure) but it didn't/doesn't still seem to be happening elsewhere in FDA
AI to understand the language of life. Our review @NatureBiotech just published https://t.co/i0WMaXBCHl Free access https://t.co/3LPulNxlD0 @VishRao5 @serena2z @BrianPlosky @pdhsu @BoWang87 @james_y_zou @marinkazitnik @pranavrajpurkar
